AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 42 min read$COR

Cencora beats top-line and bottom-line estimates; gives FY2027 outlook

Cencora reported Q4 earnings of $4.66 per share, exceeding estimates by $0.09, with revenue of $88.4B, up 5.6% year-over-year and $490M above expectations. The company provided a fiscal 2027 EPS outlook of $19.40 to $19.75, slightly below the consensus of $19.76.

Original reporting
seekingalpha.com
Published Nov 4, 2026, 11:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$COR
Bullish
high confidence
Mentioned
$COR
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CORBullishHigh
01

Why it matters

The mixed results may trigger short‑term volatility; investors may adjust positions ahead of the FY2027 guidance.

02

Market read

First‑report earnings and guidance for a large‑cap health‑care distributor, providing fresh data for traders.

03

What to watch

Potential cost‑saving initiatives and upcoming contract wins not disclosed yet.

Relevance 9/10Novelty 9/10Timing: after earnings release

Background

Cencora (formerly AmerisourceBergen) is a leading drug distributor; its earnings release is closely watched for health‑care supply‑chain trends.

Company-level read

Ticker impact

$CORBullishHigh confidence
Context

Cencora reported Q4 revenue of $88.4B beating estimates and issued FY2027 EPS guidance of $19.40‑$19.75, slightly below consensus.

Expected impact

likely downside as the market prices in the EPS guidance shortfall

Evidence & confidence

Revenue beat is modest, while EPS outlook is below consensus, a typical catalyst for a short‑term pullback.

Market effects

Sector

Pharma distribution sector may see modest re‑rating as peers' guidance is compared.

Regional

U.S. market may see slight pullback in health‑care stocks.

Global

Limited to investors tracking large‑cap distribution companies.

Counterpoint

What could challenge this read

The revenue beat could outweigh the EPS miss if the market focuses on top‑line momentum.

Key entities

  • company
    Cencora Inc.

    U.S. drug distributor reporting Q4 results.

Read at source← All news

StoryCencora reports Q4 earnings beat and issues FY2027 EPS guidance

Also covered by

2 outlets

Related articles

NOV 4
$CORMed

Cencora, Inc. (COR): Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year (As Revised) (As Revised)

Cencora, Inc. (COR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CENCORA, INC. SUMMARY REPORTABLE SEGMENT INFORMATION (in thousands) (unaudited) The following illustrates revised reportable segment revenue information for the periods indicated: Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter

SEC EDGAR 8-K2 min
NOV 4
$CORHighAI 8/10

Cencora: Fiscal Q4 Earnings Snapshot

Cencora, Inc. (COR) reported fiscal Q4 earnings of $519.4 million, or $2.71 per share, beating analyst expectations. Revenue was $88.35 billion, also exceeding forecasts. The company expects full-year earnings of $19.40 to $19.75 per share.

finance.yahoo.com2 min
NOV 4
$CORHighAI 9/10

Cencora beats estimates on earnings and revenue

Cencora Inc. (NYSE:COR) reported Q4 adjusted EPS of $4.66, beating estimates, with revenue at $88.4B, up 5.5% YoY. The company issued fiscal 2027 EPS guidance of $19.40-$19.75, above consensus. Shares dipped 0.07% in pre-market trading. Cencora also raised its dividend by 10% and reaffirmed long-term growth targets.

investing.com2 min
NOV 4
$CORHighAI 8/10

CENCORA REPORTS FISCAL 2026 FOURTH QUARTER AND FISCAL YEAR END RESULTS

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA REPORTS FISCAL 2026 FOURTH QUARTER AND FISCAL YEAR END RESULTS Fourth Quarter Revenue of $88.4 Billion up 5.5 Percent. GAAP Diluted EPS of $2.71 and Adjusted Diluted EPS of $4.66 Fiscal Year 2026 Revenue of $337.4 Billion up 5.0 Percent. GAAP Diluted EPS of $

SEC EDGAR 8-K2 min